Leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia.

Department of Environmental Health Sciences, Ann Arbor, MI, USA.
Clinical & Experimental Immunology (Impact Factor: 3.28). 12/2007; 150(2):332-9. DOI: 10.1111/j.1365-2249.2007.03491.x
Source: PubMed

ABSTRACT The adipocyte-derived hormone leptin is an important regulator of appetite and energy expenditure and is now appreciated for its ability to control innate and adaptive immune responses. We have reported previously that the leptin-deficient ob/ob mouse exhibited increased susceptibility to the Gram-negative bacterium Klebsiella pneumoniae. In this report we assessed the impact of chronic leptin deficiency, using ob/ob mice, on pneumococcal pneumonia and examined whether restoring circulating leptin to physiological levels in vivo could improve host defences against this pathogen. We observed that ob/ob mice, compared with wild-type (WT) animals, exhibited enhanced lethality and reduced pulmonary bacterial clearance following Streptococcus pneumoniae challenge. These impairments in host defence in ob/ob mice were associated with elevated levels of lung tumour necrosis factor (TNF)-alpha, macrophage inflammatory peptide (MIP)-2 [correction added after online publication 28 September 2007: definition of MIP corrected], prostaglandin E(2) (PGE(2)), lung neutrophil polymorphonuclear leukocyte (PMN) counts, defective alveolar macrophage (AM) phagocytosis and PMN killing of S. pneumoniae in vitro. Exogenous leptin administration to ob/ob mice in vivo improved survival and greatly improved pulmonary bacterial clearance, reduced bacteraemia, reconstituted AM phagocytosis and PMN H(2)O(2) production and killing of S. pneumoniae in vitro. Our results demonstrate, for the first time, that leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia. Further investigations are warranted to determine whether there is a potential therapeutic role for this adipokine in immunocompromised patients.


Available from: Peter Mancuso, Jun 16, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inhaled corticosteroids (ICS) increase community-acquired pneumonia (CAP) incidence in patients with chronic obstructive pulmonary disease (COPD) by unknown mechanisms. Apoptosis is increased in the lungs of COPD patients. Uptake of apoptotic cells (ACs) ("efferocytosis") by alveolar macrophages (AMøs) reduces their ability to combat microbes, including Streptococcus pneumoniae, the most common cause of CAP in COPD patients. Having shown that ICS significantly increase AMø efferocytosis, we hypothesized that this process, termed glucocorticoid-augmented efferocytosis, might explain the association of CAP with ICS therapy in COPD. To test this hypothesis, we studied the effects of fluticasone, AC, or both on AMøs of C57BL/6 mice in vitro and in an established model of pneumococcal pneumonia. Fluticasone plus AC significantly reduced TLR4-stimulated AMø IL-12 production, relative to either treatment alone, and decreased TNF-α, CCL3, CCL5, and keratinocyte-derived chemoattractant/CXCL1, relative to AC. Mice treated with fluticasone plus AC before infection with viable pneumococci developed significantly more lung CFUs at 48 h. However, none of the pretreatments altered inflammatory cell recruitment to the lungs at 48 h postinfection, and fluticasone plus AC less markedly reduced in vitro mediator production to heat-killed pneumococci. Fluticasone plus AC significantly reduced in vitro AMø killing of pneumococci, relative to other conditions, in part by delaying phagolysosome acidification without affecting production of reactive oxygen or nitrogen species. These results support glucocorticoid-augmented efferocytosis as a potential explanation for the epidemiological association of ICS therapy of COPD patients with increased risk for CAP, and establish murine experimental models to dissect underlying molecular mechanisms. Copyright © 2015 by The American Association of Immunologists, Inc.
    The Journal of Immunology 05/2015; DOI:10.4049/jimmunol.1402217 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article discusses obesity, its contribution to clinical outcomes, and the current literature on nutrition. More than one third of Americans are obese. Literature suggests that, among critically ill patients, the relationship between obesity and outcomes is complex. Obese patients may be at greater risk of developing acute respiratory distress syndrome (ARDS) than normal weight patients. Although obesity may confer greater morbidity in intensive care, it seems to decrease mortality. ARDS is a catabolic state; patients demonstrate a profound inflammatory response, multiple organ dysfunction, and hypermetabolism, often with malnutrition. The concept of pharmaconutrition has emerged. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.005 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been well understood that cigarette smokers have an increased risk of infections; however, the association between obesity and infections has not been well explored in general population. The analysis was based on data from the Canadian Community Health Survey - Healthy Aging (2008-2009), and included a total of 30 763 Canadians aged 45 years or older. Information on demographic data, body mass index (BMI), smoking status, chronic condition(s) and antibiotics use during the past month were collected. Logistic regression analysis was used to determine the associations of obesity and smoking with antibiotics use and adjusted for potential confounders. Overall, 6.6% used antibiotics in the previous month. Compared with those of normal weight, overweight and obese individuals were more likely to use antibiotics after adjustment for confounders, with odds ratios (ORs) of 1.28 (95% CI: 1.08, 1.50) and 1.25 (95% CI: 1.04, 1.50), respectively. When stratified by presence/absence of chronic condition(s), the associations were only significant among those with chronic condition(s) and the adjusted ORs were 1.30 (95% CI: 1.09, 1.55) for the overweight and 1.43 (95% CI: 1.18, 1.73) for the obese. Current smokers had an increased risk of antibiotics use when compared with non-smokers. The adjusted OR for smoking was similar for people with or without chronic condition(s), but was significant only for those with chronic condition(s) (OR 1.41, 95% CI: 1.16, 1.73). Overweight and obese Canadians aged 45 years or more, especially in those with chronic condition(s), had an increased risk of bacterial infections than their normal weight counterparts. The reasons for the modifying effect of chronic condition(s) on the association between body weight and infections were discussed.
    The Journal of Nutrition Health and Aging 05/2015; 19(5). DOI:10.1007/s12603-015-0472-5 · 2.66 Impact Factor